Anti-Cancer Drugs · 2005 · 128 citations · 24 references
MedicineOncologyPharmacologyApoptosisCancer PharmacologyMolecular OncologyApoptosis In CancerCancer MetabolismMalignant NeoplasmsMetabolic ReprogrammingMetabolic Reprogramming In CancerTumor Suppressor GenesCancer Cell Line ModelsDna Damage InductionNon-genotoxic CarcinogenesisOxidative Dna DamageP21 PathwayP21 RegulationP53 InactivationP53 Pathway Inactivation
The majority of human tumors bear inactive p53 or cellular factors that down-regulate the expression and activity of the p53 network. Therefore, finding therapies that are effective in such tumors is of great interest. Usnic acid, a normal component of lichens, showed activity against the wild-type p53 breast cancer cell line MCF7 as well as the non-functional p53 breast cancer cell line MDA-MB-231 and the lung cancer cell line H1299 (null for p53). In MCF7 cells treated with usnic acid, although there was an accumulation of p53 and p21 proteins, the transcriptional activity of p53 remained unaffected. We also found that there was no phosphorylation of p53 at Ser15 after treatment of MCF7 cells with usnic acid, suggesting that the oxidative stress and disruption of the normal metabolic processes of cells triggered by usnic acid does not involve DNA damage. The property of usnic acid as a non-genotoxic anti-cancer agent that works in a p53-independent manner makes it a potential candidate for novel cancer therapy.
24
p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
Scott W. Lowe, H. Earl Ruley, Tyler Jacks et al. · Cell · 1993 · 2.9K citations
Interaction of the p53-Regulated Protein Gadd45 with Proliferating Cell Nuclear Antigen
Martin L. Smith, I.-Tsuen Chen, Qimin Zhan et al. · Science · 1994 · 951 citations
Günter U. Höglinger, Géraldine Carrard, Patrick P. Michel et al. · Journal of Neurochemistry · 2003 · 254 citations · Full text